Notice: This company has been marked as potentially delisted and may not be actively trading. NantKwest (NK) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends NK vs. VIR, ADPT, PSTX, IMTX, LENZ, REPL, RLAY, AVXL, AUTL, and CGEMShould you be buying NantKwest stock or one of its competitors? The main competitors of NantKwest include Vir Biotechnology (VIR), Adaptive Biotechnologies (ADPT), Poseida Therapeutics (PSTX), Immatics (IMTX), LENZ Therapeutics (LENZ), Replimune Group (REPL), Relay Therapeutics (RLAY), Anavex Life Sciences (AVXL), Autolus Therapeutics (AUTL), and Cullinan Therapeutics (CGEM). These companies are all part of the "medical" sector. NantKwest vs. Vir Biotechnology Adaptive Biotechnologies Poseida Therapeutics Immatics LENZ Therapeutics Replimune Group Relay Therapeutics Anavex Life Sciences Autolus Therapeutics Cullinan Therapeutics NantKwest (NASDAQ:NK) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability. Is NK or VIR more profitable? Vir Biotechnology has a net margin of -678.40% compared to NantKwest's net margin of -76,658.58%. Vir Biotechnology's return on equity of -36.71% beat NantKwest's return on equity.Company Net Margins Return on Equity Return on Assets NantKwest-76,658.58% -56.06% -46.93% Vir Biotechnology -678.40%-36.71%-31.00% Which has higher earnings and valuation, NK or VIR? NantKwest has higher earnings, but lower revenue than Vir Biotechnology. NantKwest is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNantKwest$40K7,162.10-$65.79M-$0.70-3.74Vir Biotechnology$62.04M16.29-$615.06M-$3.92-1.87 Do institutionals & insiders hold more shares of NK or VIR? 9.4% of NantKwest shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 71.7% of NantKwest shares are owned by company insiders. Comparatively, 15.6% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media prefer NK or VIR? In the previous week, Vir Biotechnology had 4 more articles in the media than NantKwest. MarketBeat recorded 4 mentions for Vir Biotechnology and 0 mentions for NantKwest. Vir Biotechnology's average media sentiment score of 0.49 beat NantKwest's score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment NantKwest Neutral Vir Biotechnology Neutral Does the MarketBeat Community believe in NK or VIR? NantKwest received 224 more outperform votes than Vir Biotechnology when rated by MarketBeat users. However, 53.26% of users gave Vir Biotechnology an outperform vote while only 50.74% of users gave NantKwest an outperform vote. CompanyUnderperformOutperformNantKwestOutperform Votes27350.74% Underperform Votes26549.26% Vir BiotechnologyOutperform Votes4953.26% Underperform Votes4346.74% Do analysts recommend NK or VIR? Vir Biotechnology has a consensus target price of $36.40, indicating a potential upside of 395.91%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than NantKwest.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NantKwest 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vir Biotechnology 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has more risk & volatility, NK or VIR? NantKwest has a beta of 2.61, meaning that its share price is 161% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. SummaryVir Biotechnology beats NantKwest on 12 of the 18 factors compared between the two stocks. Ad Porter & CompanyVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Get NantKwest News Delivered to You Automatically Sign up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NK vs. The Competition Export to ExcelMetricNantKwestBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$286.48M$2.94B$5.13B$9.07BDividend YieldN/A1.90%5.08%4.23%P/E Ratio-3.6946.7389.5817.17Price / Sales7,162.10415.011,116.12116.95Price / CashN/A182.1042.8237.86Price / Book2.133.894.774.78Net Income-$65.79M-$42.21M$120.15M$225.60M NantKwest Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKNantKwestN/A$2.62-1.9%N/A-42.2%$286.48M$40,000.00-3.69160Analyst ForecastHigh Trading VolumeVIRVir Biotechnology2.0013 of 5 stars$7.63+2.4%$36.40+377.1%-25.8%$1.05B$86.18M-1.90587ADPTAdaptive Biotechnologies2.9423 of 5 stars$6.68+6.0%$6.50-2.7%+27.0%$985.83M$170.28M-4.70709Analyst ForecastNews CoverageGap DownPSTXPoseida Therapeutics3.7541 of 5 stars$9.52+0.1%$9.50-0.2%+177.1%$930.77M$64.70M-15.10260Positive NewsIMTXImmatics1.4059 of 5 stars$7.39+2.5%$16.67+125.5%-28.9%$882.04M$115.50M-10.92260LENZLENZ Therapeutics0.4939 of 5 stars$31.51+1.7%$35.40+12.3%N/A$866.56MN/A0.00N/ANews CoveragePositive NewsREPLReplimune Group4.5451 of 5 stars$12.59+0.3%$17.29+37.3%+62.2%$861.41MN/A-4.11210Insider TradeRLAYRelay Therapeutics2.2511 of 5 stars$4.90+4.0%$20.50+318.4%-61.3%$820.16M$25.55M-1.80304Insider TradeAVXLAnavex Life Sciences3.3432 of 5 stars$9.32+10.2%$43.00+361.4%-1.4%$790.34MN/A-18.5440AUTLAutolus Therapeutics2.5548 of 5 stars$2.65+6.4%$10.40+292.5%-59.4%$705.14M$1.70M-2.19330CGEMCullinan Therapeutics1.7934 of 5 stars$11.82+0.6%$31.67+167.9%+22.4%$688.26M$18.94M-4.1430News Coverage Related Companies and Tools Related Companies VIR Alternatives ADPT Alternatives PSTX Alternatives IMTX Alternatives LENZ Alternatives REPL Alternatives RLAY Alternatives AVXL Alternatives AUTL Alternatives CGEM Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NK) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NantKwest, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NantKwest With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NK Stock Alerts